Celltrion tightens grip on Asian biosimilar markets

Celltrions headquarters in Incheon Courtesy of Celltrion
Celltrion's headquarters in Incheon. Courtesy of Celltrion
 
SEOUL, November 19 (AJP) - Celltrion's biosimilars, lower-cost copies of biologic drugs, have captured the top market share in several key Asian markets, the South Korean drugmaker said Thursday.

Remsima, its autoimmune disease treatment, held 95 percent of its market in Singapore, 83 percent in Hong Kong and 75 percent in Malaysia in the second quarter, according to IQVIA data cited by the company.

Celltrion's cancer drugs also kept their lead.

Herzuma, a breast and stomach cancer treatment, held 67 percent in Hong Kong and 59 percent in Thailand, where its share jumped 17 percentage points from the previous quarter. Truxima, a blood cancer drug, took 92 percent of Singapore's market.

Vegzelma, used against metastatic colorectal and breast cancer, climbed quickly in Malaysia. It went from fourth place in the local bevacizumab market in the final quarter of 2025 to first in the first quarter, then kept the lead with a 25 percent share in the second quarter.

Celltrion plans to launch Vegzelma in Hong Kong later this month and osteoporosis drug Stoboclo in Thailand in December. Eye disease treatment Eydenzelt will follow in Singapore in February, along with allergy drug Omlyclo in Thailand.

"We will leverage the direct-sales capabilities of our local subsidiaries and the Celltrion brand to quickly establish our high-margin follow-on products," a Celltrion official said.